Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Change in Accured Expenses: 2020-2025

Historic Change in Accured Expenses for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $6.2 million.

  • Janux Therapeutics' Change in Accured Expenses rose 35.12% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year increase of 41.41%. This contributed to the annual value of $4.4 million for FY2024, which is 752.80% up from last year.
  • As of Q3 2025, Janux Therapeutics' Change in Accured Expenses stood at $6.2 million, which was up 113.58% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Change in Accured Expenses ranged from a high of $6.2 million in Q3 2025 and a low of -$2.0 million during Q3 2023.
  • Moreover, its 3-year median value for Change in Accured Expenses was $1.4 million (2023), whereas its average is $1.3 million.
  • Per our database at Business Quant, Janux Therapeutics' Change in Accured Expenses surged by 605.87% in 2022 and then plummeted by 483.57% in 2024.
  • Over the past 5 years, Janux Therapeutics' Change in Accured Expenses (Quarterly) stood at $1.9 million in 2021, then tumbled by 47.68% to $1.0 million in 2022, then crashed by 57.61% to $426,000 in 2023, then tumbled by 483.57% to -$1.6 million in 2024, then skyrocketed by 35.12% to $6.2 million in 2025.
  • Its Change in Accured Expenses was $6.2 million in Q3 2025, compared to $2.9 million in Q2 2025 and $1.7 million in Q1 2025.